

Virtual Live Programme

**PROGRAMME OF LIVE SESSIONS: CET timing**

The programme below will take place live. This time schedule corresponds to **CET timing**. [Click here \(https://www.calculator.net/time-zone-calculator.html\)](https://www.calculator.net/time-zone-calculator.html) to adapt the CET time schedule to your own time zone.

If you want to ask questions during the Panel Discussions, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting!



**2<sup>nd</sup> Translational Research E-Conference  
CHRONIC LYMPHOCYTIC LEUKAEMIA**

March 17-20, 2022

Chairpersons: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

**Thursday, March 17<sup>th</sup>, 2022**

<b>14:00–14:05</b>	<b>Welcome</b>	Jennifer Brown (Boston) Paolo Ghia (Milan) Michael Hallek (Cologne)
<b>SESSION I – Spectrum of CLL disease: MBL to Richter’s transformation</b> <b>Chairs:</b> Michael Hallek (Cologne), Silvia Deaglio (Turin)		
14:05-14:10	Introduction	Michael Hallek (Cologne) Silvia Deaglio (Turin)
14:10-14:25	MBL; low vs high count	Alberto Orfao (Salamanca)
14:25-14:40	What is the definition of high risk CLL now?	Kostas Stamatopoulos (Thessaloniki)
14:40-14:55	Richter’s Syndrome	Silvia Deaglio (Turin)
14:55-15:00	<b>Brief oral communication</b> <i>CARD9 Forms an Alternative CBM Complex in Richter Syndrome</i>	Julia Maier (Ulm)
15:00-15:30	<i>Panel discussion</i>	
<b>15:30-15:40</b>	<b>Coffee break</b>	

## Virtual Live Programme

### SESSION II – New insights in “old” biomarkers

**Chairs:** Paolo Ghia (Milan), Sarka Pospisilova (Brno)

15:40-15:45	Introduction	Paolo Ghia (Milan) Sarka Pospisilova (Brno)
15:45-16:00	Low level <i>TP53</i> clones: what is the significance?	Sarka Pospisilova (Brno)
16:00-16:15	Complex karyotype: what is relevant?	Panagiotis Baliakas (Uppsala)
16:15-16:30	How do we look at MRD in 2022	Andy Rawstron (Leeds)
16:30-16:35	<b>Brief oral communication</b> <i>Phage Display Technology for Detection, Isolation, and Gene Expression Analysis of Single Tumor Clones in Chronic Lymphocytic Leukemia</i>	Selena Mimmi (Catanzaro)
16:35-17:05	<i>Panel discussion</i>	

#### **17:15-18:15** SATELLITE SYMPOSIUM

**MRD monitoring in CLL Patients: Applicability for Clinical Management**

**Chairs & Speakers:** Carol Moreno (Barcelona), Othman Al-Sawaf (Cologne)

*This symposium is organized and sponsored by Adaptive Biotechnologies*

#### **18:25-19:25** **Mentored Poster Walk**

Leaders: Carsten Utoft Niemann (Copenhagen), Sigrid Skånland (Oslo)

**Friday, March 18<sup>th</sup>, 2022**

#### **13:00-14:00** SATELLITE SYMPOSIUM

**Translating scientific advances into clinical success in CLL**

**Chairs:** Kostas Stamatopoulos (Thessaloniki), Paolo Ghia (Milan)

**Speakers:** Richard Rosenquist (Stockholm), Carol Moreno (Barcelona)

*This symposium is organized and sponsored by Janssen*

### SESSION III – Taking driver gene mutations to the next level

**Chairs:** Jennifer Brown (Boston), Davide Rossi (Bellinzona)

14:10-14:15	Introduction	Jennifer Brown (Boston) Davide Rossi (Bellinzona)
14:15-14:30	IG mutational status and gene mutations	Richard Rosenquist (Stockholm)

## Virtual Live Programme

14:30-14:45	Understanding CLL and Richter's syndrome biology through mouse models of human genetics	Elisa Ten Hacken (Boston)
14:45-15:00	Prognostic role of rare gene mutations	Davide Rossi (Bellinzona)
15:00-15:05	<b>Brief oral communication</b> <i>Analysis of Potential miRNA-Btla mRNA Interactions in Chronic Lymphocytic Leukemia</i>	Anna Andrzejczak (Wroclaw)
15:05-15:35	<i>Panel discussion</i>	
<b>15:35-15:45</b>	<b><i>Coffee break</i></b>	

## SESSION IV – Beyond BcR: other microenvironmental stimuli

**Chairs:** Elisa Ten Hacken (Boston), Chris Pepper (Brighton)

15:45-15:50	Introduction	Elisa Ten Hacken (Boston) Chris Pepper (Brighton)
15:50-16:05	Dissecting and targeting Toll-like receptors signaling in CLL cells	Marta Muzio (Milan)
16:05-16:20	CD49d: a biologically relevant molecule and important prognostic marker in CLL	Chris Pepper (Brighton)
16:20-16:35	Effects of CXCR4- and macrophage-derived signals on the survival and growth of CLL cells	Dimitar G Efremov (Trieste)
16:35-16:50	Thrombospondin-1 and role of leukemia-associated fibroblasts	Hien Nguyen (Cologne)
16:50-17:05	Reversed microenvironmental stimuli; how CLL cells suppress T cell function	Arnon Kater (Amsterdam)
17:05-17:15	<b>Brief oral communications</b>	
	1. <i>Investigating Toll-like Receptor 9 As a Mechanism of Resistance to B-Cell Receptor-Targeted Therapies in Chronic Lymphocytic Leukaemia</i>	Emma Kennedy (Falmer)
	2. <i>Arrayed CRISPR/Cas9 Knockout Approach Identifies Novel Tyrosine Kinase Targets in CLL-Supporting Macrophages</i>	Viktoria Kohlhas (Cologne)
17:15-17:40	<i>Panel discussion</i>	

### **17:50-18:50 SATELLITE SYMPOSIUM**

#### **Treatment of CLL in the Age of Novel Agents**

**Chairs:** Jennifer Brown (Boston)

**Speakers:** Florence Cymbalista (Bobigny), Paolo Ghia (Milan)

*This symposium is organized and sponsored by AstraZenaca*

## Virtual Live Programme

### 19:00-20:00 Simultaneous Meet the Expert sessions (non-clinical)

- |                                    |  |
|------------------------------------|--|
| 1. Pathogenesis and Transformation | Elisa Ten Hacken (Boston)<br>Kostas Stamatopoulos (Thessaloniki) |
| 2. TP53 where are we standing?     | Sarka Pospisilova (Brno)<br>Arnon Kater (Amsterdam)              |

**Saturday, March 19<sup>th</sup>, 2022**

#### **13:00-14:00 SATELLITE SYMPOSIUM**

**Inhibition of Bruton's Tyrosine Kinase (BTK) – A key approach to managing and treating CLL patients**

**Chair:** Pierre Feugier (Nancy)

**Speakers:** Federico Pea (Bologna), Othman Al-Sawaf (Cologne), Wojciech Jurczak (Krakow)

*This symposium is organized and sponsored by BeiGene*

#### **SESSION V – Time-limited therapy**

**Chairs:** Arnon Kater (Amsterdam), John Allan (New York)

- |             |  |  |
|-------------|--|--|
| 14:10-14:15 | Introduction   | Arnon Kater (Amsterdam)<br>John Allan (New York) |
| 14:15-14:30 | Venetoclax antibody combinations   | Othman Al-Sawaf (Cologne)                        |
| 14:30-14:45 | BTK – BCL-2 combinations   | John Allan (New York)                            |
| 14:45-15:00 | Defined duration vs MRD driven time-limited therapy  | Talha Munir (Leeds)                              |
| 15:00-15:05 | <b>Brief oral communication</b><br><i>Induction of Neutralizing Antibodies in CLL Patients after Sars-COV-2 Mrna Vaccination</i> | Fabrizio Mavilia (Pisa)                          |
| 15:05-15:35 | <i>Panel discussion: What is the best time-limited therapy?</i>  |  |
| 15:35-15:45 | <b>Coffee break</b>  |  |

#### **SESSION VI – Covalent BTK inhibitors**

**Chairs:** Vincent Lévy (Bobigny), Othman Al-Sawaf (Cologne)

- |             |                                |   |
|-------------|--------------------------------|---|
| 15:45-15:50 | Introduction                   | Vincent Lévy (Bobigny)<br>Othman Al-Sawaf (Cologne) |
| 15:50-16:05 | Acalabrutinib and combinations | Richard Furman (New York)                           |

## Virtual Live Programme

16:05-16:20	Zanubrutinib and combinations	Alessandra Tedeschi (Milan)
16:20-16:25	<b>Brief oral communication</b> <i>Functional Role of PD-L1 in the Pathogenesis of Chronic Lymphocytic Leukaemia In Vivo</i>	Sebastian Reinartz (Cologne)
16:25-16:55	<i>Panel discussion: Which BTK inhibitor to choose? Will non-covalent BTKis replace covalents as first BTKi?</i>	
<b>16:55-17:05</b>	<b>Coffee break</b>	

## SESSION VII – BTK and Bcl2 inhibitor resistance

**Chairs:** Lukas P. Frenzel (Cologne), Adrian Wiestner (Bethesda)

17:05-17:10	Introduction	Lukas P. Frenzel (Cologne) Adrian Wiestner (Bethesda)
17:10-17:25	Resistance to covalent BTK inhibitors	Adrian Wiestner (Bethesda)
17:25-17:40	Non-covalent BTK inhibitors (ARQ531 / MK1026; pirtobrutinib)	Anthony Mato (New York)
17:40-17:55	Venetoclax resistance	Lukas P. Frenzel (Cologne)
17:55-18:00	<b>Brief oral communication</b> <i>Exploring Clonal Evolution in CLL: Analysis By Whole Exome Sequencing</i>	Kristyna Zavacka (Brno)
18:00-18:30	<i>Panel discussion: How do we overcome resistance? What happens with patients resistant to both mechanisms?</i>	

## Sunday, March 20<sup>th</sup>, 2022

### 13:00-14:00 Meet the Expert Session

Patient selection for time limited versus continued therapy	Jennifer Brown (Boston) Antony Mato (New York)
---	---

## SESSION VIII – Next generation therapies

**Chairs:** John Gribben (London), Sanne H. Tonino (Amsterdam)

14:10-14:15	Introduction	John Gribben (London) Sanne H. Tonino (Amsterdam)
14:15-14:30	Future of PI3Ks	John Gribben (London)
14:30-14:45	Beyond venetoclax: other BH3 mimetic therapies	Danielle Brander (Durham)

## Virtual Live Programme

14:45-15:00 CAR-T cell immunotherapy for CLL: a chance for cure in the era of small molecules? Marco Ruella (Philadelphia)

15:00-15:05 **Brief oral communication**  
*Subcutaneous Epcoritamab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Epcore CLL-1 Trial Results* Arnon Kater (Amsterdam)

15:05-15:35 *Panel discussion*

**15:35-15:45** *Coffee break*

## SESSION IX – The future: other targets

**Chairs:** Michael Hallek (Cologne), Jennifer Brown (Boston), Paolo Ghia (Milan)

15:45-15:50 Introduction Jennifer Brown (Boston)  
Paolo Ghia (Milan)  
Michael Hallek (Cologne)

15:50-16:05 MAPK/ERK Jennifer Brown (Boston)

16:05-16:20 CAR-T cell therapy in CLL Tanya Siddiqi (Duarte)

16:20-16:35 Cellular therapies beyond CAR-T: NK CAR, bispecifics Sanne H. Tonino (Amsterdam)

16:35-16:40 **Brief oral communication**  
*Targeting Sumoylation to Enhance T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) Models* Vi Lam (Duarte)

16:40-17:10 *Panel discussion*

**17:10-17:15** *Closing remarks* Jennifer Brown (Boston)  
Paolo Ghia (Milan)  
Michael Hallek (Cologne)

## MEETING CLOSURE